Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Innoviva (INVA) stocks in Canada

Learn how to easily invest in Innoviva stocks.

Innoviva is a biotechnology business based in the US. Innoviva stocks (INVA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.71 – a decrease of 1.92% over the previous week. Innoviva employs 5 staff and has a trailing 12-month revenue of around $374.7 million.

How to buy shares in Innoviva

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INVA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Innoviva stock price (NASDAQ:INVA)

Use our graph to track the performance of INVA stocks over time.

Innoviva shares at a glance

Information last updated 2022-01-23.
Latest market close$15.86
52-week range$10.92 - $18.97
50-day moving average $17.05
200-day moving average $15.06
Wall St. target price$10.00
PE ratio 5.2654
Dividend yield $0 (0%)
Earnings per share (TTM) $3.07

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Innoviva stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Innoviva price performance over time

Historical closes compared with the close of $15.86 from 2022-01-27

1 week (2022-01-21) -1.92%
1 month (2021-12-27) -10.65%
3 months (2021-10-29) -9.11%
6 months (2021-07-29) 12.48%
1 year (2021-01-29) 32.06%
2 years (2020-01-29) 13.12%
3 years (2019-01-29) 20.06
5 years (2017-01-27) 46.72%

Is Innoviva under- or over-valued?

Valuing Innoviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innoviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Innoviva's P/E ratio

Innoviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Innoviva shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Innoviva's PEG ratio

Innoviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Innoviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Innoviva's EBITDA

Innoviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $357.1 million.

The EBITDA is a measure of a Innoviva's overall financial performance and is widely used to measure a its profitability.

Innoviva financials

Revenue TTM $374.7 million
Operating margin TTM 95.3%
Gross profit TTM $335 million
Return on assets TTM 24.67%
Return on equity TTM 77.57%
Profit margin 82.58%
Book value $5.80
Market capitalisation $1.1 billion

TTM: trailing 12 months

Innoviva share dividends

We're not expecting Innoviva to pay a dividend over the next 12 months.

Have Innoviva's shares ever split?

Innoviva's shares were split on a 1241:1000 basis on 2 June 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1241 shares. This wouldn't directly have changed the overall worth of your Innoviva shares – just the quantity. However, indirectly, the new 19.4% lower share price could have impacted the market appetite for Innoviva shares which in turn could have impacted Innoviva's share price.

Innoviva share price volatility

Over the last 12 months, Innoviva's shares have ranged in value from as little as $10.92 up to $18.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innoviva's is 0.481. This would suggest that Innoviva's shares are less volatile than average (for this exchange).

Innoviva overview

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site